این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Acta Medica Iranica، جلد ۵۶، شماره ۲، صفحات ۹۵-۱۰۱
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی The role of ARTA followed by chemotherapy in the treatment of acute promyelocytic leukemia.
چکیده انگلیسی مقاله There are different treatment protocols available for acute promyelocytic leukemia (APL) such as all-trans retinoic acid (ATRA) plus chemotherapy or arsenic trioxide (ATO) based regimens. In this study, we focused on the role of ATRA followed by an anthracycline-containing chemotherapy regimen. This study reported the outcome of APL patients at 501 army hospital; Tehran, Iran. Seventy-three patients were included between 1995 and 2015. Treatment in our center for the majority of cases included induction with ATRA followed by Cytarabine (AraC) and an anthracycline agent (daunorubicin), and then three cycles of consolidation chemotherapy. Maintenance consisted of a 2-year period of medication with ATRA, Methotrexate (MTX) and 6-mercaptopurine (6-MP). Relapsed cases were treated with ATRA and a combination of etoposide, mitoxantrone, and cytarabine. Kaplan-Meier estimate was used to calculate survival rates. We detected 5- and 10-year overall and disease-free survival rates of 51.6% and 50.2% respectively. For those patients who survived induction deaths and received ATRA-based chemotherapy the 5-year OS and DFS rates were 68.8% and 66.5%, respectively. Hematologic complete remission (CR) was observed in all but three patients, and relapse occurred in 12 cases. The cardinal causes of induction death were disseminated intravascular coagulation (DIC) and infection. Up to the end of the follow-up time, 31 patients died including 11 cases of the relapsed disease. The combination of ATRA and chemotherapy could lead to an acceptable CR rate and relapse incidences in newly diagnosed APL patients, but more effective strategies need to be developed for screening and treatment of relapse.
کلیدواژه‌های انگلیسی مقاله
نویسندگان مقاله حسن jalaeikhoo | hasan jalaeikhoo
department of hematology and oncology, aja cancer epidemiology research and treatment center aja- certc , aja university of medical sciences, tehran, iran.


محسن رجایی نژاد | mohsen rajaeinejad
department of hematology and oncology, hematology and oncology research center, vali-e-asr hospital, tehran university of medical sciences, tehran, iran.

سازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (Tehran university of medical sciences)

manoutchehr کیهانی | manoutchehr keyhani
department of hematology and oncology, aja cancer epidemiology research and treatment center aja- certc , aja university of medical sciences, tehran, iran.


محمد ذکا اسدی | mohammad zokaasadi


نشانی اینترنتی http://acta.tums.ac.ir/index.php/acta/article/view/6360
فایل مقاله اشکال در دسترسی به فایل - ./files/site1/rds_journals/56/article-56-571554.pdf
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده Articles
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات